37.5 D-
Semax
Also known as: ACTH 4-7 Pro8-Gly9-Pro10
Emerging Research Research Chemical
Research Evidence 10.0/100
Safety Profile 65.0/100
0 Clinical Trials
No clinical trials registered for this peptide.
19 Research Papers
- Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides. Biochemistry (Mosc) unknown
- Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol unknown
- Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects. Chem Biol Drug Des unknown
- The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons. Bull Exp Biol Med unknown
- Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases. Neuropeptides Review
Showing 5 of 19 papers by citation count.
FDA Data
Not FDA-Approved
Semax has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Semax FDA approved?
No, Semax has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
What is the trust score for Semax?
Semax has a CheckPeptides trust score of 37.5/100 (grade: D-). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- ACTH analogue
- Molecular Weight
- 813.9 Da
- PubChem
- CID 9811102 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 10.0/100
Safety Profile 65.0/100
Evidence Summary
- Clinical Trials
- 0
- Research Papers
- 19
- Trust Score
- 37.5/100
- Grade
- D-